Patent SG-11201805268X-A (SG)
Title: T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex
Inventor: CHESTER FIONA
IPC: C12N5/0783
Filed: 2016-12-22
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau „ (10) International Publication Number (43) International Publication Date ^ ^ WO 2017/109496 A1 29 June 2017 (29.06.2017) WIPO I PCT (51) International Patent Classification: C07K14/725 (2006.01) A61P 35/00 (2006.01) A61K39/00 (2006.01) C07K14/47 (2006.01) C12N 5/0783 (2010.01) (21) International Application Number: PCT/GB2016/054032 (22) International Filing Date: 22 December 2016 (22.12.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1522592.3 22 December 2015 (22.12.2015) GB (71) Applicant: IMMUNOCORE LIMITED [GB/GB]; 101 Park Drive, Milton Park, Abingdon Oxfordshire OX 14 4RY (GB). (72) Inventors: CHESTER, Fiona; Immunocore Limited, 101 Park Drive, Milton Park, Abingdon Oxfordshire OX 14 4RY (GB). KNOX, Andrew Alexander; Immunocore Limited, 101 Park Drive, Milton Park, Abingdon Oxford­ shire OX14 4RY (GB). LOWTHER, Jonathan Patrick; Immunocore Limited, 101 Park Drive, Milton Park, Abing­ don Oxfordshire OX14 4RY (GB). PATEL, Viren Vinubhai; Immunocore Limited, 101 Park Drive, Milton Park, Abingdon Oxfordshire OX14 4RY (GB). BASTON, Emma Elizabeth; Immunocore Limited, 101 Park Drive, Milton Park, Abingdon Oxfordshire OX14 4RY (GB). HAGUE, Ruth Martinez; Immunocore Limited, 101 Park Drive, Milton Park, Abingdon Oxfordshire OX 14 4RY (GB). (74) Agent: CARE, Alison; Kilburn & Strode LLP, 20 Red Lion Street, London Greater London WC1R 4PJ (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) (54) Title: T CELL RECEPTORS SPECIFIC FOR THE NY-ESO-1 TUMOR ANTIGEN-HLA-A*02 COMPLEX FIG. 9 Functional testing of immTAC molecules of the invention (Exp. No. PCAG0S) NY-ESO-1+ve cells (NCS-H1755) o\ o\ © 500 s 400 300 (D y." 200 -i L_ <f>~ o S 100 0 • immTACI immTAC2 !mmTAC3 imm'TAC4 [immTAC] nM o CJ (57) : The present invention relates to T cell receptors (TCRs) which bind the HLA-A*02 restricted peptide SLLMWITQC derived from the cancer antigen NY-ESO-1. Said TCRs may comprise mutations within the alpha and/or beta variable domains relat­ ive to a native NY-ESO-1 TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.